HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS

Corporate Research, 1 Gambro AB; Analytical Chemistry, 2 University of Lund, Lund, Sweden Correspondence to: M. Erixon, Gambro Lundia AB, Box 10101, S-220 10 Lund, Sweden. martin.erixon{at}gambro.com Objective: The formation of glucose degradation products (GDPs) during sterilization of peritoneal d...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Peritoneal Dialysis International 2006-07, Vol.26 (4), p.490-497
Hauptverfasser: Erixon, Martin, Wieslander, Anders, Linden, Torbjorn, Carlsson, Ola, Forsback, Gunita, Svensson, Eva, Jonsson, Jan Ake, Kjellstrand, Per
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 497
container_issue 4
container_start_page 490
container_title Peritoneal Dialysis International
container_volume 26
creator Erixon, Martin
Wieslander, Anders
Linden, Torbjorn
Carlsson, Ola
Forsback, Gunita
Svensson, Eva
Jonsson, Jan Ake
Kjellstrand, Per
description Corporate Research, 1 Gambro AB; Analytical Chemistry, 2 University of Lund, Lund, Sweden Correspondence to: M. Erixon, Gambro Lundia AB, Box 10101, S-220 10 Lund, Sweden. martin.erixon{at}gambro.com Objective: The formation of glucose degradation products (GDPs) during sterilization of peritoneal dialysis fluids (PDFs) is one of the most important aspects of biocompatibility of glucose-containing PDFs. Producers of PDFs are thus trying to minimize the level of GDPs in their products. 3,4-Dideoxyglucosone-3-ene (3,4-DGE) has been identified as the most bioreactive GDP in PDFs. It exists in a temperature-dependent equilibrium with a pool of 3-deoxyglucosone (3-DG) and is a precursor in the irreversible formation of 5-hydroxymethyl furaldehyde (5-HMF). The aim of the present study was to investigate how to minimize GDPs in PDFs and how different manufacturers have succeeded in doing so. Design: Glucose solutions at different pHs and concentrations were heat sterilized and 3-DG, 3,4-DGE, 5-HMF, formaldehyde, and acetaldehyde were analyzed. Conventional as well as biocompatible fluids from different manufacturers were analyzed in parallel for GDP concentrations. Results: The concentrations of 3-DG and 3,4-DGE produced during heat sterilization decreased when pH was reduced to about 2. Concentration of 5-HMF decreased when pH was reduced to 2.6. After further decrease to a pH of 2.0, concentration of 5-HMF increased slightly, and below a pH of 2.0 it increased considerably, together with formaldehyde; 3-DG continued to drop and 3,4-DGE remained constant. Inhibition of cell growth was paralleled by 3,4-DGE concentration at pH 2.0 – 6.0. A high glucose concentration lowered concentrations of 3,4-DGE and 3-DG at pH 5.5 and of 5-HMF at pH 1. At pH 2.2 and 3.2, glucose concentration had a minor effect on the formation of GDPs. All conventional PDFs contained high levels of 3,4-DGE and 3-DG. Concentrations were considerably lower in the biocompatible fluids. However, the concentration of 5-HMF was slightly higher in all the biocompatible fluids. Conclusion: The best way to avoid reactive GDPs is to have a pH between 2.0 and 2.6 during sterilization. If pHs outside this range are used, it becomes more important to have high glucose concentration during the sterilization process. There are large variations in GDPs, both within and between biocompatible and conventionally manufactured PDFs. KEY WORDS: 3,4-DGE; glucose degradation products; cytotoxicity; pH; glucose; PD
doi_str_mv 10.1177/089686080602600414
format Article
fullrecord <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68703338</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68703338</sourcerecordid><originalsourceid>FETCH-LOGICAL-c444t-ea81ad9455df361bdee021fab36882f27f6d93bfd7c5ec02503e96abacd02c933</originalsourceid><addsrcrecordid>eNplkU9vm0AQxVdRq8RJ-gV6qLg0N9rZP-wuR2SIg4RCZXCqnlYL7DZEOHZYI5Rv37VstYcenmYOv3kzmofQZwzfMBbiO8iYSw4SOBAOwDC7QAsssAwZBfYBLY5AeCSu0LVzLwCUUBCX6ApzKTFl0QKtHsqfQV0GyVOZp8Gq2CzLKgvSbLVO0qTOy8fgx7pMN8u6CnLfZ-u8Lh-zpAjSPCl-VXkV3BebPK1u0UerB2c-nesN2txn9fIhLMpVvkyKsGWMHUKjJdZdzKKos5TjpjMGCLa6of4iYomwvItpYzvRRqYFEgE1MdeNbjsgbUzpDSpOvm42-6lR-7Hf6vFd7XSvhmnv1XgpZ5QAa0lDhYqNxIpZwpWOKFeCUhoRKiLLwNvdnez24-5tMu6gtr1rzTDoV7ObnOJSgOelB8kJbMedc6OxfzdjUMc01P9p-KEvZ_ep2Zru38j5_R74egKe-9_Pcz8a5bZ6GDxO1DzP_mSmWAz0D8-cif8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68703338</pqid></control><display><type>article</type><title>HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Erixon, Martin ; Wieslander, Anders ; Linden, Torbjorn ; Carlsson, Ola ; Forsback, Gunita ; Svensson, Eva ; Jonsson, Jan Ake ; Kjellstrand, Per</creator><creatorcontrib>Erixon, Martin ; Wieslander, Anders ; Linden, Torbjorn ; Carlsson, Ola ; Forsback, Gunita ; Svensson, Eva ; Jonsson, Jan Ake ; Kjellstrand, Per</creatorcontrib><description>Corporate Research, 1 Gambro AB; Analytical Chemistry, 2 University of Lund, Lund, Sweden Correspondence to: M. Erixon, Gambro Lundia AB, Box 10101, S-220 10 Lund, Sweden. martin.erixon{at}gambro.com Objective: The formation of glucose degradation products (GDPs) during sterilization of peritoneal dialysis fluids (PDFs) is one of the most important aspects of biocompatibility of glucose-containing PDFs. Producers of PDFs are thus trying to minimize the level of GDPs in their products. 3,4-Dideoxyglucosone-3-ene (3,4-DGE) has been identified as the most bioreactive GDP in PDFs. It exists in a temperature-dependent equilibrium with a pool of 3-deoxyglucosone (3-DG) and is a precursor in the irreversible formation of 5-hydroxymethyl furaldehyde (5-HMF). The aim of the present study was to investigate how to minimize GDPs in PDFs and how different manufacturers have succeeded in doing so. Design: Glucose solutions at different pHs and concentrations were heat sterilized and 3-DG, 3,4-DGE, 5-HMF, formaldehyde, and acetaldehyde were analyzed. Conventional as well as biocompatible fluids from different manufacturers were analyzed in parallel for GDP concentrations. Results: The concentrations of 3-DG and 3,4-DGE produced during heat sterilization decreased when pH was reduced to about 2. Concentration of 5-HMF decreased when pH was reduced to 2.6. After further decrease to a pH of 2.0, concentration of 5-HMF increased slightly, and below a pH of 2.0 it increased considerably, together with formaldehyde; 3-DG continued to drop and 3,4-DGE remained constant. Inhibition of cell growth was paralleled by 3,4-DGE concentration at pH 2.0 – 6.0. A high glucose concentration lowered concentrations of 3,4-DGE and 3-DG at pH 5.5 and of 5-HMF at pH 1. At pH 2.2 and 3.2, glucose concentration had a minor effect on the formation of GDPs. All conventional PDFs contained high levels of 3,4-DGE and 3-DG. Concentrations were considerably lower in the biocompatible fluids. However, the concentration of 5-HMF was slightly higher in all the biocompatible fluids. Conclusion: The best way to avoid reactive GDPs is to have a pH between 2.0 and 2.6 during sterilization. If pHs outside this range are used, it becomes more important to have high glucose concentration during the sterilization process. There are large variations in GDPs, both within and between biocompatible and conventionally manufactured PDFs. KEY WORDS: 3,4-DGE; glucose degradation products; cytotoxicity; pH; glucose; PD fluids; bioreactive. Received 7 November 2005; accepted 3 February 2006.</description><identifier>ISSN: 0896-8608</identifier><identifier>ISSN: 1718-4304</identifier><identifier>EISSN: 1718-4304</identifier><identifier>DOI: 10.1177/089686080602600414</identifier><identifier>PMID: 16881345</identifier><language>eng</language><publisher>United States</publisher><subject>4-DGE ; Animals ; bioreactive ; Cell Division ; Clinical Medicine ; cytotoxicity ; Dialysis Solutions - analysis ; Dialysis Solutions - chemistry ; Dialysis Solutions - classification ; fluids ; glucose ; Glucose - analogs &amp; derivatives ; Glucose - analysis ; Glucose - metabolism ; glucose degradation products ; Humans ; Hydrogen-Ion Concentration ; Klinisk medicin ; L Cells ; Medical and Health Sciences ; Medicin och hälsovetenskap ; Mice ; Peritoneal Dialysis - methods ; Urologi och njurmedicin ; Urology and Nephrology</subject><ispartof>Peritoneal Dialysis International, 2006-07, Vol.26 (4), p.490-497</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c444t-ea81ad9455df361bdee021fab36882f27f6d93bfd7c5ec02503e96abacd02c933</citedby><cites>FETCH-LOGICAL-c444t-ea81ad9455df361bdee021fab36882f27f6d93bfd7c5ec02503e96abacd02c933</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16881345$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://lup.lub.lu.se/record/399022$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Erixon, Martin</creatorcontrib><creatorcontrib>Wieslander, Anders</creatorcontrib><creatorcontrib>Linden, Torbjorn</creatorcontrib><creatorcontrib>Carlsson, Ola</creatorcontrib><creatorcontrib>Forsback, Gunita</creatorcontrib><creatorcontrib>Svensson, Eva</creatorcontrib><creatorcontrib>Jonsson, Jan Ake</creatorcontrib><creatorcontrib>Kjellstrand, Per</creatorcontrib><title>HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS</title><title>Peritoneal Dialysis International</title><addtitle>Perit Dial Int</addtitle><description>Corporate Research, 1 Gambro AB; Analytical Chemistry, 2 University of Lund, Lund, Sweden Correspondence to: M. Erixon, Gambro Lundia AB, Box 10101, S-220 10 Lund, Sweden. martin.erixon{at}gambro.com Objective: The formation of glucose degradation products (GDPs) during sterilization of peritoneal dialysis fluids (PDFs) is one of the most important aspects of biocompatibility of glucose-containing PDFs. Producers of PDFs are thus trying to minimize the level of GDPs in their products. 3,4-Dideoxyglucosone-3-ene (3,4-DGE) has been identified as the most bioreactive GDP in PDFs. It exists in a temperature-dependent equilibrium with a pool of 3-deoxyglucosone (3-DG) and is a precursor in the irreversible formation of 5-hydroxymethyl furaldehyde (5-HMF). The aim of the present study was to investigate how to minimize GDPs in PDFs and how different manufacturers have succeeded in doing so. Design: Glucose solutions at different pHs and concentrations were heat sterilized and 3-DG, 3,4-DGE, 5-HMF, formaldehyde, and acetaldehyde were analyzed. Conventional as well as biocompatible fluids from different manufacturers were analyzed in parallel for GDP concentrations. Results: The concentrations of 3-DG and 3,4-DGE produced during heat sterilization decreased when pH was reduced to about 2. Concentration of 5-HMF decreased when pH was reduced to 2.6. After further decrease to a pH of 2.0, concentration of 5-HMF increased slightly, and below a pH of 2.0 it increased considerably, together with formaldehyde; 3-DG continued to drop and 3,4-DGE remained constant. Inhibition of cell growth was paralleled by 3,4-DGE concentration at pH 2.0 – 6.0. A high glucose concentration lowered concentrations of 3,4-DGE and 3-DG at pH 5.5 and of 5-HMF at pH 1. At pH 2.2 and 3.2, glucose concentration had a minor effect on the formation of GDPs. All conventional PDFs contained high levels of 3,4-DGE and 3-DG. Concentrations were considerably lower in the biocompatible fluids. However, the concentration of 5-HMF was slightly higher in all the biocompatible fluids. Conclusion: The best way to avoid reactive GDPs is to have a pH between 2.0 and 2.6 during sterilization. If pHs outside this range are used, it becomes more important to have high glucose concentration during the sterilization process. There are large variations in GDPs, both within and between biocompatible and conventionally manufactured PDFs. KEY WORDS: 3,4-DGE; glucose degradation products; cytotoxicity; pH; glucose; PD fluids; bioreactive. Received 7 November 2005; accepted 3 February 2006.</description><subject>4-DGE</subject><subject>Animals</subject><subject>bioreactive</subject><subject>Cell Division</subject><subject>Clinical Medicine</subject><subject>cytotoxicity</subject><subject>Dialysis Solutions - analysis</subject><subject>Dialysis Solutions - chemistry</subject><subject>Dialysis Solutions - classification</subject><subject>fluids</subject><subject>glucose</subject><subject>Glucose - analogs &amp; derivatives</subject><subject>Glucose - analysis</subject><subject>Glucose - metabolism</subject><subject>glucose degradation products</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Klinisk medicin</subject><subject>L Cells</subject><subject>Medical and Health Sciences</subject><subject>Medicin och hälsovetenskap</subject><subject>Mice</subject><subject>Peritoneal Dialysis - methods</subject><subject>Urologi och njurmedicin</subject><subject>Urology and Nephrology</subject><issn>0896-8608</issn><issn>1718-4304</issn><issn>1718-4304</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNplkU9vm0AQxVdRq8RJ-gV6qLg0N9rZP-wuR2SIg4RCZXCqnlYL7DZEOHZYI5Rv37VstYcenmYOv3kzmofQZwzfMBbiO8iYSw4SOBAOwDC7QAsssAwZBfYBLY5AeCSu0LVzLwCUUBCX6ApzKTFl0QKtHsqfQV0GyVOZp8Gq2CzLKgvSbLVO0qTOy8fgx7pMN8u6CnLfZ-u8Lh-zpAjSPCl-VXkV3BebPK1u0UerB2c-nesN2txn9fIhLMpVvkyKsGWMHUKjJdZdzKKos5TjpjMGCLa6of4iYomwvItpYzvRRqYFEgE1MdeNbjsgbUzpDSpOvm42-6lR-7Hf6vFd7XSvhmnv1XgpZ5QAa0lDhYqNxIpZwpWOKFeCUhoRKiLLwNvdnez24-5tMu6gtr1rzTDoV7ObnOJSgOelB8kJbMedc6OxfzdjUMc01P9p-KEvZ_ep2Zru38j5_R74egKe-9_Pcz8a5bZ6GDxO1DzP_mSmWAz0D8-cif8</recordid><startdate>20060701</startdate><enddate>20060701</enddate><creator>Erixon, Martin</creator><creator>Wieslander, Anders</creator><creator>Linden, Torbjorn</creator><creator>Carlsson, Ola</creator><creator>Forsback, Gunita</creator><creator>Svensson, Eva</creator><creator>Jonsson, Jan Ake</creator><creator>Kjellstrand, Per</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D95</scope></search><sort><creationdate>20060701</creationdate><title>HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS</title><author>Erixon, Martin ; Wieslander, Anders ; Linden, Torbjorn ; Carlsson, Ola ; Forsback, Gunita ; Svensson, Eva ; Jonsson, Jan Ake ; Kjellstrand, Per</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c444t-ea81ad9455df361bdee021fab36882f27f6d93bfd7c5ec02503e96abacd02c933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>4-DGE</topic><topic>Animals</topic><topic>bioreactive</topic><topic>Cell Division</topic><topic>Clinical Medicine</topic><topic>cytotoxicity</topic><topic>Dialysis Solutions - analysis</topic><topic>Dialysis Solutions - chemistry</topic><topic>Dialysis Solutions - classification</topic><topic>fluids</topic><topic>glucose</topic><topic>Glucose - analogs &amp; derivatives</topic><topic>Glucose - analysis</topic><topic>Glucose - metabolism</topic><topic>glucose degradation products</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Klinisk medicin</topic><topic>L Cells</topic><topic>Medical and Health Sciences</topic><topic>Medicin och hälsovetenskap</topic><topic>Mice</topic><topic>Peritoneal Dialysis - methods</topic><topic>Urologi och njurmedicin</topic><topic>Urology and Nephrology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Erixon, Martin</creatorcontrib><creatorcontrib>Wieslander, Anders</creatorcontrib><creatorcontrib>Linden, Torbjorn</creatorcontrib><creatorcontrib>Carlsson, Ola</creatorcontrib><creatorcontrib>Forsback, Gunita</creatorcontrib><creatorcontrib>Svensson, Eva</creatorcontrib><creatorcontrib>Jonsson, Jan Ake</creatorcontrib><creatorcontrib>Kjellstrand, Per</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Lunds universitet</collection><jtitle>Peritoneal Dialysis International</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Erixon, Martin</au><au>Wieslander, Anders</au><au>Linden, Torbjorn</au><au>Carlsson, Ola</au><au>Forsback, Gunita</au><au>Svensson, Eva</au><au>Jonsson, Jan Ake</au><au>Kjellstrand, Per</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS</atitle><jtitle>Peritoneal Dialysis International</jtitle><addtitle>Perit Dial Int</addtitle><date>2006-07-01</date><risdate>2006</risdate><volume>26</volume><issue>4</issue><spage>490</spage><epage>497</epage><pages>490-497</pages><issn>0896-8608</issn><issn>1718-4304</issn><eissn>1718-4304</eissn><abstract>Corporate Research, 1 Gambro AB; Analytical Chemistry, 2 University of Lund, Lund, Sweden Correspondence to: M. Erixon, Gambro Lundia AB, Box 10101, S-220 10 Lund, Sweden. martin.erixon{at}gambro.com Objective: The formation of glucose degradation products (GDPs) during sterilization of peritoneal dialysis fluids (PDFs) is one of the most important aspects of biocompatibility of glucose-containing PDFs. Producers of PDFs are thus trying to minimize the level of GDPs in their products. 3,4-Dideoxyglucosone-3-ene (3,4-DGE) has been identified as the most bioreactive GDP in PDFs. It exists in a temperature-dependent equilibrium with a pool of 3-deoxyglucosone (3-DG) and is a precursor in the irreversible formation of 5-hydroxymethyl furaldehyde (5-HMF). The aim of the present study was to investigate how to minimize GDPs in PDFs and how different manufacturers have succeeded in doing so. Design: Glucose solutions at different pHs and concentrations were heat sterilized and 3-DG, 3,4-DGE, 5-HMF, formaldehyde, and acetaldehyde were analyzed. Conventional as well as biocompatible fluids from different manufacturers were analyzed in parallel for GDP concentrations. Results: The concentrations of 3-DG and 3,4-DGE produced during heat sterilization decreased when pH was reduced to about 2. Concentration of 5-HMF decreased when pH was reduced to 2.6. After further decrease to a pH of 2.0, concentration of 5-HMF increased slightly, and below a pH of 2.0 it increased considerably, together with formaldehyde; 3-DG continued to drop and 3,4-DGE remained constant. Inhibition of cell growth was paralleled by 3,4-DGE concentration at pH 2.0 – 6.0. A high glucose concentration lowered concentrations of 3,4-DGE and 3-DG at pH 5.5 and of 5-HMF at pH 1. At pH 2.2 and 3.2, glucose concentration had a minor effect on the formation of GDPs. All conventional PDFs contained high levels of 3,4-DGE and 3-DG. Concentrations were considerably lower in the biocompatible fluids. However, the concentration of 5-HMF was slightly higher in all the biocompatible fluids. Conclusion: The best way to avoid reactive GDPs is to have a pH between 2.0 and 2.6 during sterilization. If pHs outside this range are used, it becomes more important to have high glucose concentration during the sterilization process. There are large variations in GDPs, both within and between biocompatible and conventionally manufactured PDFs. KEY WORDS: 3,4-DGE; glucose degradation products; cytotoxicity; pH; glucose; PD fluids; bioreactive. Received 7 November 2005; accepted 3 February 2006.</abstract><cop>United States</cop><pmid>16881345</pmid><doi>10.1177/089686080602600414</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0896-8608
ispartof Peritoneal Dialysis International, 2006-07, Vol.26 (4), p.490-497
issn 0896-8608
1718-4304
1718-4304
language eng
recordid cdi_proquest_miscellaneous_68703338
source Access via SAGE; MEDLINE
subjects 4-DGE
Animals
bioreactive
Cell Division
Clinical Medicine
cytotoxicity
Dialysis Solutions - analysis
Dialysis Solutions - chemistry
Dialysis Solutions - classification
fluids
glucose
Glucose - analogs & derivatives
Glucose - analysis
Glucose - metabolism
glucose degradation products
Humans
Hydrogen-Ion Concentration
Klinisk medicin
L Cells
Medical and Health Sciences
Medicin och hälsovetenskap
Mice
Peritoneal Dialysis - methods
Urologi och njurmedicin
Urology and Nephrology
title HOW TO AVOID GLUCOSE DEGRADATION PRODUCTS IN PERITONEAL DIALYSIS FLUIDS
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T17%3A42%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HOW%20TO%20AVOID%20GLUCOSE%20DEGRADATION%20PRODUCTS%20IN%20PERITONEAL%20DIALYSIS%20FLUIDS&rft.jtitle=Peritoneal%20Dialysis%20International&rft.au=Erixon,%20Martin&rft.date=2006-07-01&rft.volume=26&rft.issue=4&rft.spage=490&rft.epage=497&rft.pages=490-497&rft.issn=0896-8608&rft.eissn=1718-4304&rft_id=info:doi/10.1177/089686080602600414&rft_dat=%3Cproquest_swepu%3E68703338%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68703338&rft_id=info:pmid/16881345&rfr_iscdi=true